Symbols

CANF

Can-fite Biopharma·AMEX

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CANF

Can-Fite Biopharma Ltd.

A company that developing small molecule therapeutics to treat autoimmune-inflammatory, oncological and ophthalmic diseases

Industry

Pharmaceutical

Established Date

09/11/1994

Listing Date

11/19/2013

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.canfite.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

26 Ben Gurion Street Ramat Gan 5257346 Israel

Business

Advanced clinical-stage biopharmaceutical company.

Introduction

Can-fite Biopharma Ltd., was founded on September 11, 1994. The company is a late-stage clinical biopharmaceutical company developing oral small molecule therapies targeting the A3 adenosine receptor for the treatment of cancer, liver and inflammatory diseases. Its main drug candidates include Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma and metabolic dysfunction-associated steatohepatitis.

Company Financials

EPS

CANF has released its 2023 Q3 earnings. EPS was reported at -0.43, versus the expected -0.44, beating expectations. The chart below visualizes how CANF has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CANF has released its 2023 Q4 earnings report, with revenue of 155.00K, reflecting a YoY change of -21.32%, and net profit of -1.65M, showing a YoY change of 45.28%. The Sankey diagram below clearly presents CANF's revenue sources and cost distribution.